Copyright
©The Author(s) 2017.
World J Gastrointest Pharmacol Ther. May 6, 2017; 8(2): 131-136
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.131
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.131
Table 2 Demographics and characteristics of patients
| Gender | |
| Male | 77 (61.6%) |
| Female | 48 (38.4%) |
| Mean age at diagnosis | 33.6 (range: 10-80) |
| Smoke | |
| No | 76 (70.8%) |
| Yes | 26 (20.8%) |
| Former | 23 (18.4%) |
| Family history | |
| No | 106 (84.8%) |
| Yes | 19 (15.2%) |
| Appendicectomy | |
| No | 116 (92.8%) |
| Yes | 9 (7.2%) |
| Characteristics of disease | |
| Ulcerative colitis | 64 (51.2%) |
| Crohn’s disease | 61 (48.8%) |
| Duration of disease at 1st infusion (median) | 52 mo (IQR: 16-110.5) |
| Duration of follow-up (median) | 34 mo (IQR: 19-55.5) |
- Citation: Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. World J Gastrointest Pharmacol Ther 2017; 8(2): 131-136
- URL: https://www.wjgnet.com/2150-5349/full/v8/i2/131.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v8.i2.131